Should You Buy Emergent BioSolutions Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Emergent BioSolutions Inc. (EBS) occupies a solid middle-ground position with a Quality of Company score of 7.1/10. At the current market price of $6.36, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 7 of 9 CirclFi valuation models project upside for Emergent BioSolutions Inc. (EBS) at $6.36 — the model consensus leans bullish, with a Quality Score of 7.1/10 and Value-Trap risk of 34/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Emergent BioSolutions Inc. (EBS) in 2026?
What Is the Bull Case vs the Bear Case for Emergent BioSolutions Inc. (EBS)?
| Bull case — $29.05 target (+356.7%) | Bear case — $1.02 target (-83.9%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Emergent BioSolutions Inc.'s quality score of 7.1/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $1.02 (-83.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $6.36 and the median fair value of $14.65 implies +130.3% upside potential. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +440.6% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model targets a fair value of $29.05 (+356.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: clinical trial failure represents a meaningful risk for Emergent BioSolutions Inc. and its Drug Manufacturers - Specialty & Generic peers. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Emergent BioSolutions Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. |
How Does EBS Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: IRWD · LQDA · ETON · TAK · INDV · HROW · VTRS · PLNH · AMPH · UTHR
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like EBS on Quality?
Closest companies to EBS’s Quality of Company score of 7.1/10, across all industries.
- OSCR — Oscar Health, Inc. (QOC 7.1) · analysis
- ASTH — Astrana Health, Inc. (QOC 7.1) · analysis
- MS — Morgan Stanley (QOC 7.1) · analysis
- AOUT — American Outdoor Brands, Inc. (QOC 7.1) · analysis
- NMR — Nomura Holdings, Inc. (QOC 7.1) · analysis
- ASAN — Asana, Inc. (QOC 7.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does EBS Appear In?
So Is Emergent BioSolutions Inc. (EBS) Worth Buying in 2026?
The convergence of 7.1/10 quality, multi-model undervaluation (7/9 bullish, +130.3% median upside), and a median fair value of $14.65 vs. $6.36 current price makes Emergent BioSolutions Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Emergent BioSolutions Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About EBS Stock?
Should I buy EBS stock right now?
Based on CirclFi's multi-model analysis, 7 of 9 models see upside for EBS at $6.36. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.1/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Emergent BioSolutions Inc.?
Key risks include: wide model disagreement (2740% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does EBS compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, EBS holds a Quality Score of 7.1/10. Comparable companies include IRWD (QOC 7.1), LQDA (QOC 7.0), ETON (QOC 7.2). The relative ranking helps investors identify whether EBS offers better fundamental quality than alternatives in the same sector.
Is EBS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. EBS's Quality Score of 7.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy EBS at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $1.02 to $29.05. At $6.36, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for EBS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad